Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers

Advanced Cancer Clinical Trial

Official title:

Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02245204
• Other study ID #: LYS-I-01
• Status: Completed
• Phase: Phase 1
• Start date: September 2014
• Est. completion date: October 2016

Study information

• Verified date: October 2018
• Source: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study:

Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced malignant tumor subjects;

Description:

1. Investigate the tolerance of Chlorogenic acid for injection in human body, determine the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for injection in the advanced malignant tumor subjects;

2. Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection;

3. Preliminary observation the effectiveness and effective dose;

4. Provide the basis for the dosage regimen of phase II/III.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: October 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients with pathologic or/and FNAC confirmation of advanced cancer but without effective treatment or with treatment failure;

2. Between 18 and 65 years of age, KPS=70;

3. According to RECIST 1.1,patients with at least one tumor lesion that can accurately be measured by CT or MRI in at least one dimension with longest diameter to be recorded as >2.0cm by general CT or >1.0cm by spiral CT;

4. Life expectancy of at least three (3) months at the enrollment;

5. Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:

• PLT count=100×10~9/L,

• WLB count=4.0×10~9/L and =12×10~9/L,

• Neutrophil granulocyte count=2.0×10~9/L,

• HGB count=90g/L,

• Total bilirubin <=1.5 times of ULN,

• ALT/AST =2.5 times of ULN,

• SCr=1.5 times of ULN,

• Normal ECG with LVEF (=50%) measured by echocardiography;

6. Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months;

7. Volunteered for the phase 1 trial and sign the informed consent without protest;

Exclusion Criteria:

1. Patients who have received large area radiotherapy (>30% marrow capacity);

2. Patients who suffer from other serious complication, such as uncontrollable infection, myocardial infarction within the past 6 months at the enrollment , uncontrollable hypertension ,thromboembolism and etc.;

3. Symptomatic patients with brain metastases (except for the patients whose brain metastases is controlled to stable status after whole brain radiotherapy);

4. Patients who have received the therapy of chemotherapy within 4 weeks before enrollment;

5. Patients who have used nitrosoureas drug or mitomycin within 6 weeks or tyrosine kinase inhibitor within 2 weeks before enrollment;

6. Patients who have received therapy of major surgery within 6 weeks or biopsy surgery within 2 weeks before enrollment;

7. Patients who or have received radical radiotherapy within 6 weeks or local palliative radiotherapy within 2 weeks before enrollment;

8. Patients who experience grade 2 or more than grade 2 toxicity caused by the past therapies;

9. Patients who have history of drug abuse or alcoholism;

10. Patients who smoke over 5 cigarettes or equivalent tobacco per day;

11. Uncontrollable psychopaths;

12. Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;

13. Patients who had received a therapy of another investigational drug within 4 weeks or patients who are still in another clinical trial at the enrollment;

14. Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;

15. Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters;

16. Allergic to the investigational drug;

17. Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).

Related Conditions & MeSH terms

• Advanced Cancer
• Neoplasms

Intervention

Drug:
• Chlorogenic acid
Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity=98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd	Beijing Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changing in number of red blood cell and level of hemoglobin		within 1 year after the first dose of chlorogenic acid
Other	Changing in the diameters of lymph node metastasis		Within 1 year after the first dose of chlorogenic acid
Other	Changing in levels of tumor markers		Within 1 year after the first dose of chlorogenic acid
Primary	Number of adverse events		Within the first 60 days after the first dose of chlorogenic acid
Secondary	Dose-Limiting Toxicity		Within the first 30 days after the first dose of chlorogenic acid
Secondary	Maximum Tolerated Dose		Within the first 30 days after the first dose of chlorogenic acid
Secondary	Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of chlorogenic acid		Within the first 30 days after the first dose of chlorogenic acid
Secondary	Improvement in cancer-related symptoms and quality of life		Within 1 year after the first dose of chlorogenic acid